Status:
COMPLETED
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
Lead Sponsor:
AstraZeneca
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) ...
Eligibility Criteria
Inclusion
- 18 years or older, established coronary heart disease with a previously performed PCI, previous treatment with clopidogrel, ongoing statin treatment, LDL-C\>2.9 mmol/L, signed informed consent.
Exclusion
- Ongoing treatment with clopidogrel for more than 12 weeks after randomisation, hypersensitivity to any of the study drugs, active liver disease, moderate or severe renal impairment, hereditary for or known muscular or neuromuscular disease and/or increased serum CK, pregnancy or lactation or of childbearing potential not practising an adequate method of contraception, use of concomitant medication with possible interaction with
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00235950
Start Date
January 1 2004
End Date
March 1 2006
Last Update
November 19 2010
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Danderyd, Sweden
2
Research Site
Eksjö, Sweden
3
Research Site
Falun, Sweden
4
Research Site
Gothenburg, Sweden